Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03829241 · ClinicalTrials.gov registry record · Phase 3
Randomized Trial of Adult Participants With Generalized Anxiety Disorder
A Phase 3 study, sponsored by Biohaven Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 881
- Enrollment target
NCT03829241: Completed Phase 3 study, sponsored by Biohaven Pharmaceuticals.
NCT03829241 is a Phase 3 study that has completed, run by Biohaven Pharmaceuticals. The registered enrollment target is 881 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03829241, a Phase 3 study, has completed, sponsored by Biohaven Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 881 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of troriluzole versus placebo in participants with generalized anxiety disorder.
Primary Outcome
The HAM-A was an investigator-administered scale and consisted of 14 items: anxious mood, tension, fears, insomnia, concentration, depressed mood, behavior at interview, somatic muscular, somatic sensory, cardiovascular, respiratory, gastrointestinal, genitourinary, and autonomic symptoms. Each item was scored on a scale of 0 (not present) to 4 (severe) with a total score range of 0-56. A decreased score indicated a decrease in anxiety symptoms.
Interventions
- DRUG Placebo
- DRUG Troriluzole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 881 participants |
| Start Date | 2019-02-19 |
| Est. Completion | 2020-05-08 |
| Phase | Phase 3 |
What the finished NCT03829241 record still lists
NCT03829241 is an interventional study that assigns participants to a tested intervention. The registered 881 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03829241 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03829241 about?
NCT03829241 is a clinical study titled "Randomized Trial of Adult Participants With Generalized Anxiety Disorder". The purpose of this study is to compare the efficacy of troriluzole versus placebo in participants with generalized anxiety disorder.
What is the current status of trial NCT03829241?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 881 participants. The study started on 2019-02-19. Estimated completion is 2020-05-08.
What interventions are being tested in trial NCT03829241?
The interventions under investigation include: Placebo (DRUG), Troriluzole (DRUG).
Who is sponsoring clinical trial NCT03829241?
This trial is sponsored by Biohaven Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03829241's enrollment target sits among peer trials
881 367th of 2000 higher than 1,634 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07196748 · 882 participants · Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
- NCT05525663 · 880 participants · NA
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI